ADC Therapeutics SA — Form 6-K Summary
Business Context and Reporting Period
ADC Therapeutics SA, a Swiss biopharmaceutical company and foreign private issuer, furnished this Form 6-K for December 2022. The filing reports executive leadership changes announced on December 19, 2022.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Jose “Pepe” Carmona was appointed Chief Financial Officer in December 2022.
- Jennifer Creel is leaving the Company to pursue other opportunities and will serve as an advisor during the transition.
- Chief Accounting Officer Robert A. Schmidt notified the Company of his resignation, effective December 30, 2022.
- Mr. Carmona previously served as CFO of Rubius Therapeutics and Radius Health and held senior financial management roles at Innocoll and Novartis.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The CFO transition and pending departure of the Chief Accounting Officer are the principal reported corporate developments. No material compensation, related-party relationship, or family relationship involving Mr. Carmona was disclosed; the filing states that no family relationships exist between him and the Company’s directors or executive officers.
Investor Verification Items
- Verify the effective date and transition arrangements for the Chief Financial Officer and Chief Accounting Officer changes.
- Review Exhibit 99.1, the December 19, 2022 press release, for additional management commentary or terms.
- Consult the Company’s subsequent Form 20-F and other filings for any effects of the leadership changes on financial reporting, controls, guidance, or liquidity.